NO794171L - Polymerforbindelse for frigjoering av 5-aminosalisylsyre eller salter derav i mave/tarmkanalen - Google Patents

Polymerforbindelse for frigjoering av 5-aminosalisylsyre eller salter derav i mave/tarmkanalen

Info

Publication number
NO794171L
NO794171L NO794171A NO794171A NO794171L NO 794171 L NO794171 L NO 794171L NO 794171 A NO794171 A NO 794171A NO 794171 A NO794171 A NO 794171A NO 794171 L NO794171 L NO 794171L
Authority
NO
Norway
Prior art keywords
compound according
skeleton
polymer
salicylic acid
compound
Prior art date
Application number
NO794171A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas M Parkinson
Joseph P Brown
Robert E Wingard
Original Assignee
Dynapol Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/971,609 external-priority patent/US4190716A/en
Application filed by Dynapol Corp filed Critical Dynapol Corp
Publication of NO794171L publication Critical patent/NO794171L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G85/00General processes for preparing compounds provided for in this subclass
    • C08G85/004Modification of polymers by chemical after-treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/795Polymers containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/30Introducing nitrogen atoms or nitrogen-containing groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/34Introducing sulfur atoms or sulfur-containing groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48Polymers modified by chemical after-treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
NO794171A 1978-12-20 1979-12-19 Polymerforbindelse for frigjoering av 5-aminosalisylsyre eller salter derav i mave/tarmkanalen NO794171L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/971,609 US4190716A (en) 1978-12-20 1978-12-20 Polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US06/095,411 US4298595A (en) 1978-12-20 1979-11-29 Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract

Publications (1)

Publication Number Publication Date
NO794171L true NO794171L (no) 1980-06-23

Family

ID=26790195

Family Applications (1)

Application Number Title Priority Date Filing Date
NO794171A NO794171L (no) 1978-12-20 1979-12-19 Polymerforbindelse for frigjoering av 5-aminosalisylsyre eller salter derav i mave/tarmkanalen

Country Status (16)

Country Link
US (1) US4298595A (de)
EP (1) EP0013000B1 (de)
AT (1) AT366068B (de)
AU (1) AU535100B2 (de)
CA (1) CA1130281A (de)
DE (1) DE2966737D1 (de)
DK (1) DK541879A (de)
ES (1) ES8101630A1 (de)
FI (1) FI793991A7 (de)
GR (1) GR68718B (de)
IL (1) IL58969A (de)
IT (1) IT1162426B (de)
MC (1) MC1302A1 (de)
NO (1) NO794171L (de)
NZ (1) NZ192458A (de)
PT (1) PT70615A (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
WO1984004041A1 (en) * 1983-04-14 1984-10-25 Univ California Colon-specific drug delivery system
GB8401166D0 (en) * 1984-01-17 1984-02-22 Bevaloid Ltd Labelled polymer compositions
US4663308A (en) * 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
US5032572A (en) * 1984-07-18 1991-07-16 Medical College Of Ohio Polymers containing cross-linked azo bonds, which polymers are useful for releasing therapeutic agents into the lower gastrointestinal tract
US5484605A (en) * 1988-11-25 1996-01-16 Henning Berlin Gmbh Chemie-Und Pharmawerk Agent for treating chronically inflammatory intestinal diseases
BE1003677A3 (nl) * 1990-01-29 1992-05-19 Schacht Etienne Werkwijze voor het bereiden van azobevattende polymeren en het gebruik ervan als geneesmiddelafgiftesystemen.
US5120306A (en) * 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US7122615B1 (en) * 1998-09-10 2006-10-17 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
DE19813613A1 (de) 1998-03-27 1999-09-30 Jochen Kerres Modifiziertes Polymer und modifizierte Polymermembran
US20040038948A1 (en) 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
WO2002009769A2 (en) * 2000-07-27 2002-02-07 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
EP1642885B1 (de) 2000-08-29 2009-11-11 Biocon Limited Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
AU2003251992A1 (en) * 2002-07-17 2004-02-02 Rutgers, The State University Therapeutic devices for patterned cell growth
HUE029189T2 (en) 2004-02-06 2017-02-28 Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome
KR20130028807A (ko) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 방사선 유발성 장염의 예방, 치료 및 개선 방법
HUE028158T2 (en) 2004-07-07 2016-12-28 Biocon Ltd Synthesis of bound immunoregulatory compounds
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102670626A (zh) * 2005-08-24 2012-09-19 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20100048519A1 (en) * 2006-09-13 2010-02-25 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis using aminosalicylate
AU2006348180A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis
EP2102144A4 (de) 2006-09-13 2011-03-23 Univ Rutgers Wirkstoffe und ihre oligomere und polymere
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
BR112012027520A2 (pt) 2010-04-26 2015-09-15 Salix Pharmaceuticals Ltd formulações e usos de derivados de ácido 2-hidroxi-5-fenilazobenzoico para o tratamento de indivíduos do sexo masculino
US8741317B2 (en) 2010-08-19 2014-06-03 Rutgers, The State University Of New Jersey Slow-degrading polymers comprising salicylic acid for undelayed and sustained drug delivery
US9144579B2 (en) 2012-08-17 2015-09-29 Rutgers, The State University Of New Jersey Polyesters and methods of use thereof
US20140120057A1 (en) 2012-10-25 2014-05-01 Rutgers, The State University Of New Jersey Polymers and methods thereof for wound healing
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
WO2014194055A1 (en) 2013-05-29 2014-12-04 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
US10023521B2 (en) 2014-06-13 2018-07-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
WO2016164898A1 (en) 2015-04-10 2016-10-13 Rutgers, The State University Of New Jersey Kojic acid polymers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862312A (en) * 1968-01-08 1975-01-21 Ici Ltd Compositions comprising a resinate of dl- or l-tetramisole, and treatment therewith
US3920855A (en) * 1973-11-30 1975-11-18 Dynapol Corp Food containing non-toxic food coloring compositions and a process therefor
US4096134A (en) * 1975-12-08 1978-06-20 Dynapol Ethylsulfonate-alkylamine copolymers as colorant backbones

Also Published As

Publication number Publication date
IT1162426B (it) 1987-04-01
EP0013000A2 (de) 1980-07-09
AU535100B2 (en) 1984-03-01
MC1302A1 (fr) 1980-10-03
AT366068B (de) 1982-03-10
PT70615A (en) 1980-01-01
GR68718B (de) 1982-02-04
ES487081A0 (es) 1980-12-16
IT7951122A0 (it) 1979-12-18
DK541879A (da) 1980-06-21
IL58969A (en) 1983-05-15
NZ192458A (en) 1984-07-06
CA1130281A (en) 1982-08-24
ATA802479A (de) 1981-07-15
AU5399579A (en) 1980-07-10
US4298595A (en) 1981-11-03
ES8101630A1 (es) 1980-12-16
IL58969A0 (en) 1980-03-31
EP0013000B1 (de) 1984-02-29
FI793991A7 (fi) 1981-01-01
EP0013000A3 (en) 1981-01-21
DE2966737D1 (en) 1984-04-05

Similar Documents

Publication Publication Date Title
EP0013000B1 (de) Polymerer Wirkstoff zum Freisetzen von 5-Aminosalicylsäure oder ihrer Derivate im Gastrointestinaltrakt, diesen Wirkstoff enthaltende pharmazeutische Zusammensetzung, Verfahren zur Herstellung des Wirkstoffs und Verfahren zur Herstellung dieser Zusammensetzung
US4814437A (en) Method for preparation of sulfated polysaccharides by treating the polysaccharide with a reducing agent before sulfation
IL46125A (en) Non-toxic paint mixture, process for its preparation and a food substance mixed with it
US4190716A (en) Polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
Kurita et al. Synthetic carbohydrate polymers containing trehalose residues in the main chain: preparation and characteristic properties
CA1114997A (en) Polyvinylbenzenesulfonic acids
US2395347A (en) Sulphur-containing esters of hydrolyzed ethylene-vinyl organic ester interpolymers
Jana et al. Anti-respiratory syncytial virus and anti-herpes simplex virus activity of chemically engineered sulfated fucans from Cystoseira indica
US4826826A (en) Methylated chitosans and their use for the preparation of pharmaceutical compositions
CH629841A5 (de) Verfahren zur verbesserung der loeslichkeit eines polymeren farbstoffes in sauren waessrigen medien.
GB2090843A (en) Substituted Polyarylethersulphone Copolymers
ITMI970611A1 (it) Emulsionanti anti-incendio polivalenti comprendenti un polisaccaride e un polimero fluorurato a tre blocchi
CN101274964B (zh) 一种水溶性高取代度纤维素硫酸钠的制备方法
CN107362747B (zh) 一种高分子阴离子型壳聚糖表面活性剂及制备方法
AU648556B2 (en) Therapeutic composition containing hydrolysed carboxyalkyl cellulose
JP2511675B2 (ja) ポリオキシエチレン化キチンの製造方法
PL439753A1 (pl) Sposób otrzymywania kwasu diglikolowego
Avadi et al. N, N-diethyl N-methyl chitosan as an enhancing agent for colon drug delivery
JP2687141B2 (ja) 新規なキトサン化合物、該化合物の製造方法および該化合物を含む保湿剤
EP2107072A1 (de) Natriumresorptionsinhibitor, kaliumresorptionsinhibitor, phosphorresorptionsinhibitor und präventivmittel, therapeutisches mittel und lebensmittel damit
WO1998003184A1 (en) Levan derivatives, their preparation, composition and applications including medical and food applications
JP2511676B2 (ja) ポリオキシエチレン化キチンの酸化物の製造方法
JPH0632804A (ja) キチン誘導体の製造方法
JP4961144B2 (ja) 抗ウイルス剤
US3887175A (en) Quinidine alginate and process of preparation thereof